Crohn's & Colitis Foundation of America selects Wiley to publish Inflammatory Bowel Diseases

March 20, 2006

Global publisher John Wiley & Sons, Inc., announced today that it has been selected by the Crohn's & Colitis Foundation of America (CCFA) as the new publisher of the Foundation's official journal, Inflammatory Bowel Diseases, effective January 2007.

Inflammatory Bowel Diseases is the first and only peer-reviewed journal dedicated exclusively to inflammatory bowel diseases. Now in its tenth year, the journal provides articles of interest to professionals treating patients and conducting research in this expanding field. Each issue contains articles on clinical and basic science, as well as reviews of treatments and ground-breaking research.

"This is a wonderful partnership opportunity for Wiley," said Shawn Morton, Wiley Vice President and Publishing Director, Medicine. "We look forward to facilitating communication about the mechanisms and treatment of Crohn's disease and ulcerative colitis through this premier publication in collaboration with CCFA."

Wiley will begin publishing the journal in 2007 and will continue to make it available in print and online as a benefit of CCFA Professional Membership, and through subscription to other individual and institutional customers. Inflammatory Bowel Diseases will be available online via Wiley InterScience (www.interscience.wiley.com), the company's online publishing platform.

"CCFA is extremely proud of this journal, which provides an important forum for the best and the brightest scientists and clinicians in our field to report on the advances that are being made," said Jonathan Braun, M.D., Ph.D., Professor, David Geffen School of Medicine, UCLA Medical Center, and Chair of CCFA's National Scientific Advisory Committee. "We're confident that our partnership with Wiley will allow us to build on the journal's success, and expand our outreach to the medical community."
-end-
About John Wiley & Sons, Inc.
Founded in 1807, John Wiley & Sons, Inc., provides must-have content and services to customers worldwide. Its core businesses include scientific, technical, and medical journals, encyclopedias, books, and online products and services; professional and consumer books and subscription services; and educational materials for undergraduate and graduate students and lifelong learners. Wiley has publishing, marketing, and distribution centers in the United States, Canada, Europe, Asia, and Australia. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb. Wiley's Internet site can be accessed at http://www.wiley.com.

About Crohn's & Colitis Foundation of America
The Crohn's & Colitis Foundation of America's (CCFA) mission is to cure and prevent Crohn's disease and ulcerative colitis through research, and to improve the quality of life of children and adults affected by these digestive diseases through education and support. More than 80 cents of every dollar the Foundation spends goes to mission-critical programs. CCFA consistently meets the standards of organizations that monitor charities, including the Better Business Bureau's Wise Giving Alliance (give.org) and the American Institute of Philanthropy (charitywatch.org). For more information, contact CCFA at 800-932-2423 or visit www.ccfa.org.

Wiley

Related Inflammatory Bowel Diseases Articles from Brightsurf:

Cell therapy designed to treat inflammatory bowel disease
The UPV/EHU's NanoBioCel research group has for many years been developing systems enabling cells to be used as drugs.

Antibiotics associated with increased risk of inflammatory bowel disease
Antibiotics use, particularly antibiotics with greater spectrum of microbial coverage, may be associated with an increased risk of new-onset inflammatory bowel disease (IBD) and its subtypes ulcerative colitis and Crohn's disease.

Management of inflammatory bowel diseases: Clinical perspectives
In a new special issue of Clinical Gastroenterology and Hepatology, the clinical practice journal of the American Gastroenterological Association (AGA), leading international experts provide a comprehensive update on the treatment of inflammatory bowel diseases (IBD) for the practicing clinician

The effects of inflammatory bowel disease on pregnancy
Inflammatory bowel disease (IBD) -- including Crohn's disease and ulcerative colitis -- often affects women of childbearing age.

5 major advances in inflammatory bowel disease (IBD) treatment
Summary of five impactful studies to be presented at the Crohn's & Colitis Congress, a partnership of the Crohn's & Colitis Foundation and the American Gastroenterological Association (AGA).

Researchers identify a possible cause and treatment for inflammatory bowel disease
In a study published online in PNAS on Jan. 20, 2020, Prof.

Does inflammatory bowel disease carry certain risks during pregnancy?
Pregnant women with inflammatory bowel disease (IBD) are more likely to undergo delivery by Caesarean section and face certain risks during pregnancy, according to an analysis published in Alimentary Pharmacology & Therapeutics.

Inhibiting a protease could improve the treatment of inflammatory bowel disease
Scientists at the CNIC and CSIC have identified a function of a protease that could be the future target of drugs to treat inflammatory bowel disease.

Are steroids used too much for patients with inflammatory bowel disease?
Steroid therapy is commonly used to treat acute attacks of the inflammatory bowel diseases ulcerative colitis and Crohn's disease; however, because it does not provide long-term benefits and it carries a risk of serious side effects, it should not be used to treat inflammatory bowel disease for more than three months.

FODMAPs diet relieves symptoms of inflammatory bowel disease
New research from King's College London has found that a diet low in fermented carbohydrates has improved certain gut symptoms and improved health-related quality of life for sufferers of inflammatory bowel disease (IBD).

Read More: Inflammatory Bowel Diseases News and Inflammatory Bowel Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.